$1.07 EPS Expected for Steris PLC (STE) This Quarter

Wall Street analysts expect that Steris PLC (NYSE:STE) will report $1.07 earnings per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Steris’ earnings. The highest EPS estimate is $1.11 and the lowest is $1.04. Steris reported earnings of $0.98 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 9.2%. The business is scheduled to report its next quarterly earnings results on Tuesday, February 6th.

On average, analysts expect that Steris will report full-year earnings of $4.06 per share for the current year, with EPS estimates ranging from $4.04 to $4.08. For the next fiscal year, analysts anticipate that the company will post earnings of $4.53 per share, with EPS estimates ranging from $4.50 to $4.57. Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Steris.

Steris (NYSE:STE) last posted its earnings results on Wednesday, November 1st. The medical equipment provider reported $0.94 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.95 by ($0.01). The company had revenue of $634.20 million for the quarter, compared to analysts’ expectations of $629.02 million. Steris had a net margin of 5.59% and a return on equity of 11.49%. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.89 EPS.

STE has been the subject of a number of recent analyst reports. KeyCorp reaffirmed an “overweight” rating and set a $101.00 target price (up previously from $91.00) on shares of Steris in a report on Thursday, November 2nd. Zacks Investment Research lowered Steris from a “buy” rating to a “sell” rating in a report on Monday, November 6th. TD Securities lifted their target price on Steris from C$14.00 to C$16.00 and gave the company a “buy” rating in a report on Thursday, November 9th. Finally, Raymond James Financial lifted their target price on Steris from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, October 16th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Steris presently has a consensus rating of “Buy” and a consensus price target of $79.50.

Steris (STE) opened at $86.95 on Wednesday. The company has a current ratio of 2.80, a quick ratio of 2.18 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $7,364.68, a PE ratio of 22.32 and a beta of 1.27. Steris has a twelve month low of $65.26 and a twelve month high of $93.39.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 20th. Stockholders of record on Wednesday, November 22nd were issued a dividend of $0.31 per share. This represents a $1.24 annualized dividend and a dividend yield of 1.43%. The ex-dividend date was Tuesday, November 21st. Steris’s payout ratio is 73.81%.

In other news, insider Michael J. Tokich sold 11,000 shares of the business’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $92.00, for a total transaction of $1,012,000.00. Following the completion of the transaction, the insider now owns 58,588 shares of the company’s stock, valued at $5,390,096. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP John Adam Zangerle sold 3,650 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total value of $321,200.00. The disclosure for this sale can be found here. 2.55% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC boosted its stake in Steris by 1,972.4% in the second quarter. Janus Henderson Group PLC now owns 7,679,507 shares of the medical equipment provider’s stock worth $625,880,000 after buying an additional 7,308,950 shares in the last quarter. BlackRock Inc. boosted its stake in Steris by 33.4% in the second quarter. BlackRock Inc. now owns 7,032,984 shares of the medical equipment provider’s stock worth $573,188,000 after buying an additional 1,760,879 shares in the last quarter. Vanguard Group Inc. boosted its stake in Steris by 1.6% in the second quarter. Vanguard Group Inc. now owns 6,879,760 shares of the medical equipment provider’s stock worth $560,700,000 after buying an additional 107,644 shares in the last quarter. FMR LLC boosted its stake in Steris by 33.1% in the second quarter. FMR LLC now owns 3,454,533 shares of the medical equipment provider’s stock worth $281,544,000 after buying an additional 859,228 shares in the last quarter. Finally, State Street Corp boosted its stake in Steris by 53.2% in the second quarter. State Street Corp now owns 2,336,074 shares of the medical equipment provider’s stock worth $190,392,000 after buying an additional 811,622 shares in the last quarter. 89.40% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was posted by Week Herald and is owned by of Week Herald. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://weekherald.com/2018/01/13/1-07-eps-expected-for-steris-plc-ste-this-quarter.html.

About Steris

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Get a free copy of the Zacks research report on Steris (STE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply